Short-course Fluoroquinolones in Acute Exacerbations of Chronic Bronchitis

Mark H Gotfried; Ronald F Grossman


Expert Rev Resp Med. 2010;4(5):661-672. 

In This Article


Search Strategy & Selection Criteria

We searched the MEDLINE database from January 1 1990 to February 24 2009 for all relevant randomized controlled clinical trials that used short-course fluoroquinolone regimens to treat AECB. Search terms included 'acute exacerbation(s) of chronic bronchitis', 'fluoroquinolone', 'moxifloxacin', 'levofloxacin', 'gemifloxacin', '5 day(s)', 'short' and 'recovery'. We selected studies that were conducted in humans and published in English. Our exclusion criteria included studies not targeting AECB patients, studies that used fluoroquinolones for more than 5 days or studies not using respiratory fluoroquinolones to treat AECB. Publications without original data or quantitative outcomes were also excluded. Owing to our exclusion of studies not published in English, there may be some studies that are not included in this review.

Study Characteristics

Two sets of clinical studies were identified. One compared the effectiveness of short-course (≤5 days) treatment with a respiratory fluoroquinolone on clinical and microbiological outcomes in AECB with that of other antimicrobial therapies for 7 days or more. The second addressed the effects of 5-day, short-course fluoroquinolone therapy on the speed of recovery from AECB. Data on study design, number of patients, treatment regimen, duration of treatment, clinical outcomes (clinical cure rate and clinical success rate) in the per-protocol (PP) population and intent-to-treat (ITT) populations, and microbiological outcomes were extracted from the identified studies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: